FDA approves Teva inhaler with dose counter
NORTH WALES, Pa. — The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.
Teva announced the approval of the inhaled drug ProAir HFA (albuterol sulfate) with a dose counter for treating bronchospasm with reversible obstructive airway disease and preventing exercise-induced bronchospasm in patients ages 4 years and older. The dose counter is designed to help patients and caregivers keep track of the number of doses in the canister.
"Short-acting beta-agonists like ProAir are an essential component of clinical treatment guidelines for asthma, [chronic obstructive pulmonary disease] and EIB," Teva SVP global respiratory research and development Tushar Shah said. "The dose counter is designed to help patients, as well as their healthcare providers, keep track of the number of doses remaining in the inhaler."
The company plans to launch the new inhalers later in the year.
FidoPharm launches Pet Trust Plus
NEW ORLEANS — A company that makes pet drugs has launched what it calls the first generic prescription heartworm preventive medication for sale at retail pharmacies around the country.
FidoPharm announced the launch of Pet Trust Plus (ivermectin and pyrantel), a generic version of Merial’s Heartgard Plus. The drug is meant to prevent heartworms from developing and reaching a dog’s arteries and heart.
"Dogs deserve access to preventive heartworm medicine, and their owners deserve choices without having to sacrifice quality and efficacy," FidoPharm president Alex Kaufman said. "With the introduction of Pet Trust Plus at retail pharmacies nationwide, FidoPharm continues to protect pets and provide pet parents with affordable and accessible pet healthcare options, and we are proud to educate pet owners about the importance of heartworm testing and treatment."
APhA, ADA announce new collaboration
WASHINGTON — A new partnership aims to educate pharmacists, other healthcare professionals, caregivers and patients about diabetes and about how pharmacists can work with physicians to help patients manage the condition.
The American Pharmacists Association, the APhA Foundation and the American Diabetes Association announced the collaboration Friday, saying it would develop new resources and also promote existing programs, such as the ADA’s Stop Diabetes Movement and the APhA’s Pharmaceutical Care for Patients with Diabetes certification program.
"Pharmacists are the medication experts and the most accessible healthcare provider," APhA EVP and CEO Thomas Menighan said. "According to the CDC, 84% of adults with diabetes are using medications as therapy. There may be several different medications these patients are taking, and this is an excellent opportunity for pharmacists to talk with these patients and ensure that the patients understand the medications and the conditions they are trying to treat."